GenMark Diagnostics, Inc., a molecular diagnostics company, develops and commercializes molecular tests based on its proprietary eSensor electrochemical detection technology. It provides ePlex instrument and respiratory pathogen panel, which integrates automated nucleic acid extraction and amplification with its eSensor detection technology to enable operators using ePlex system to place patient sample directly into its test cartridge and obtain results. The company offers XT-8 instrument, and related diagnostic and research tests, as well as certain custom manufactured reagents that enable reference laboratories and hospitals to support a range of molecular tests with a workstation and disposable test cartridges. It also provides diagnostic tests for use with its XT-8 system that includes respiratory viral panel, cystic fibrosis genotyping test, thrombophilia risk test, a warfarin sensitivity test, and hepatitis C virus genotyping test and associated custom manufactured reagents, as well as 2C19 genotyping test. The company sells its products through direct sales and technically specialized service organization in the United States and Europe. GenMark Diagnostics, Inc. is headquartered in Carlsbad, California.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:GNMK
Previous Symbol
CUSIPN/A
Phone760-448-4300
Debt
Debt-to-Equity Ratio0.69
Current Ratio3.75
Quick Ratio3.10
Price-To-Earnings
Trailing P/E Ratio-4.16
Forward P/E Ratio-5.85
P/E GrowthN/A
Sales & Book Value
Annual Sales$52.52 million
Price / Sales5.36
Cash FlowN/A
Price / Cash FlowN/A
Book Value$1.29 per share
Price / Book3.90
Profitability
EPS (Most Recent Fiscal Year)($1.21)
Net Income$-61,850,000.00
Net Margins-79.33%
Return on Equity-95.36%
Return on Assets-50.74%
Miscellaneous
Employees517
Outstanding Shares55,960,000
Market Cap$281.45 million
OptionableOptionable
GenMark Diagnostics (NASDAQ:GNMK) Frequently Asked Questions
What is GenMark Diagnostics' stock symbol?
GenMark Diagnostics trades on the NASDAQ under the ticker symbol "GNMK."
How were GenMark Diagnostics' earnings last quarter?
GenMark Diagnostics, Inc (NASDAQ:GNMK) released its earnings results on Monday, October, 29th. The medical equipment provider reported ($0.20) earnings per share for the quarter, hitting the Zacks' consensus estimate of ($0.20). The medical equipment provider earned $15.80 million during the quarter, compared to analyst estimates of $15.76 million. GenMark Diagnostics had a negative net margin of 79.33% and a negative return on equity of 95.36%. View GenMark Diagnostics' Earnings History.
When is GenMark Diagnostics' next earnings date?
What guidance has GenMark Diagnostics issued on next quarter's earnings?
GenMark Diagnostics issued an update on its FY 2018 earnings guidance on Monday, October, 29th. The company provided EPS guidance of for the period. The company issued revenue guidance of $68-72 million, compared to the consensus revenue estimate of $71 million.
What price target have analysts set for GNMK?
3 brokers have issued twelve-month price targets for GenMark Diagnostics' stock. Their forecasts range from $9.00 to $11.00. On average, they anticipate GenMark Diagnostics' share price to reach $10.3333 in the next twelve months. This suggests a possible upside of 105.4% from the stock's current price. View Analyst Price Targets for GenMark Diagnostics.
What is the consensus analysts' recommendation for GenMark Diagnostics?
3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for GenMark Diagnostics in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for GenMark Diagnostics.
What are Wall Street analysts saying about GenMark Diagnostics stock?
Here are some recent quotes from research analysts about GenMark Diagnostics stock:
- 1. According to Zacks Investment Research, "GenMark Diagnostics, Inc. is a molecular diagnostics company focused on developing and commercializing its proprietary eSensor(R) detection technology. The eSensor® XT-8 system is the second generation in GenMark Dx's eSensor® platform, utilizing electrochemical detection technology to detect nucleic acids on a microarray. The XT-8 System enables multiplex detection of DNA and RNA targets. The Company has developed four diagnostic tests for use with its XT-8 System. Its Cystic Fibrosis Genotyping Test, which detects pre-conception risks of cystic fibrosis, and its Warfarin Sensitivity Test, which determines an individual's ability to metabolize the oral anticoagulant warfarin, have received FDA clearance. It has also developed a Respiratory Viral Panel Test, which detects the presence of major respiratory viruses, and a Thrombosis Risk Test, which detects an individual's increased risk of blood clots. GenMark Diagnostics, Inc. is based in Pasadena, California. " (12/5/2018)
- 2. Needham & Company LLC analysts commented, "GNMK’s 2Q18 revenue beat while its EPS missed consensus. Management reiterated its 2018 revenue and ePlex placement guidance. GNMK placed 39 ePlex systems in 2Q18, up from 32 in 1Q18 and above our estimate of 35. Increased utilization drove consumables revenue growth and GNMK’s gross margin improved from 1Q18. We believe the 2Q18 results are further evidence that the ePlex launch is gaining momentum. We continue to expect increased utilization of a growing ePlex installed base to continue to drive strong revenue growth (and eventually, improved gross margins) and we reiterate our Buy rating." (7/31/2018)
Has GenMark Diagnostics been receiving favorable news coverage?
Media coverage about GNMK stock has trended very positive recently, according to InfoTrie Sentiment. The research group identifies positive and negative news coverage by monitoring more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. GenMark Diagnostics earned a coverage optimism score of 3.9 on InfoTrie's scale. They also gave headlines about the medical equipment provider a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an impact on the stock's share price in the immediate future.
Who are some of GenMark Diagnostics' key competitors?
Some companies that are related to GenMark Diagnostics include Orthofix Medical (OFIX), Cryolife (CRY), Cardiovascular Systems (CSII), Tactile Systems Technology (TCMD), Intersect ENT (XENT), AngioDynamics (ANGO), SurModics (SRDX), OraSure Technologies (OSUR), Cerus (CERS), LeMaitre Vascular (LMAT), Antares Pharma (ATRS), SI-Bone (SIBN), Inovio Pharmaceuticals (INO), Anika Therapeutics (ANIK) and Orthopediatrics (KIDS).
Who are GenMark Diagnostics' key executives?
GenMark Diagnostics' management team includes the folowing people:
- Mr. Hany Massarany, CEO, Pres & Director (Age 57)
- Mr. Scott Mendel, Chief Financial Officer (Age 51)
- Mr. Michael Gleeson, Sr. VP of Corp. Accounts (Age 43)
- Mr. Brian Andrew Mitchell, Sr. VP of Operations (Age 53)
- Mr. Johnny Ek, VP of Fin. & Accounting and Corp. Controller
Who are GenMark Diagnostics' major shareholders?
GenMark Diagnostics' stock is owned by a number of of retail and institutional investors. Top institutional shareholders include FMR LLC (14.94%), JPMorgan Chase & Co. (7.89%), JPMorgan Chase & Co. (7.89%), BlackRock Inc. (6.45%), Putnam Investments LLC (6.24%) and Vanguard Group Inc. (4.67%). Company insiders that own GenMark Diagnostics stock include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, Jon Faiz Kayyem, Michael Gleeson, Michael Kagnoff and Scott Mendel. View Institutional Ownership Trends for GenMark Diagnostics.
Which major investors are selling GenMark Diagnostics stock?
GNMK stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC, Morgan Stanley, Citadel Advisors LLC, Private Wealth Partners LLC, Thrivent Financial for Lutherans, Jefferies Group LLC and Russell Investments Group Ltd.. Company insiders that have sold GenMark Diagnostics company stock in the last year include Brian Andrew Mitchell, Eric Stier, Hany Massarany, James B Mcnally, Jennifer Anne Williams, Michael Gleeson and Scott Mendel. View Insider Buying and Selling for GenMark Diagnostics.
Which major investors are buying GenMark Diagnostics stock?
GNMK stock was bought by a variety of institutional investors in the last quarter, including BlackRock Inc., Bellevue Group AG, FMR LLC, JPMorgan Chase & Co., JPMorgan Chase & Co., Vanguard Group Inc., Engineers Gate Manager LP and Virtu Financial LLC. View Insider Buying and Selling for GenMark Diagnostics.
How do I buy shares of GenMark Diagnostics?
Shares of GNMK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is GenMark Diagnostics' stock price today?
One share of GNMK stock can currently be purchased for approximately $5.03.
How big of a company is GenMark Diagnostics?
GenMark Diagnostics has a market capitalization of $281.45 million and generates $52.52 million in revenue each year. The medical equipment provider earns $-61,850,000.00 in net income (profit) each year or ($1.21) on an earnings per share basis. GenMark Diagnostics employs 517 workers across the globe.
What is GenMark Diagnostics' official website?
How can I contact GenMark Diagnostics?
GenMark Diagnostics' mailing address is 5964 LA PLACE COURT, CARLSBAD CA, 92008. The medical equipment provider can be reached via phone at 760-448-4300 or via email at [email protected]
MarketBeat Community Rating for GenMark Diagnostics (NASDAQ GNMK)
MarketBeat's community ratings are surveys of what our community members think about GenMark Diagnostics and other stocks. Vote "Outperform" if you believe GNMK will outperform the S&P 500 over the long term. Vote "Underperform" if you believe GNMK will underperform the S&P 500 over the long term. You may vote once every thirty days.
